Ghost Tree Capital’s Acceleron Pharma XLRN Stock Holding History

Ghost Tree Capital’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-200,000	Closed	-$8.49M	–	66
2017 Q4	$8.49M	Sell	200,000 -150,000	-43%	-$5.63M	1.99%	17
2017 Q3	$13.1M	Buy	350,000 +260,000	+289%	+$9.03M	2.77%	10
2017 Q2	$2.73M	Sell	90,000 -310,000	-78%	-$8.98M	0.57%	56
2017 Q1	$10.6M	Buy	400,000 +360,000	+900%	+$9.49M	1.97%	14
2016 Q4	$1.02M	Buy	+40,000	New	+$1.27M	0.25%	62

Other funds holding XLRN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Ghost Tree Capital's XLRN Position: Q1 2018 in Review

Ghost Tree Capital sold out of Acceleron Pharma (XLRN) in Q1 2018, closing a stake of 200,000 shares — an estimated $8.49M sold.

Ghost Tree Capital first reported a position in XLRN in Q4 2016 and held it in 5 quarters. The position peaked at $13.1M in Q3 2017. 150 funds tracked by Wall St. Rank hold XLRN as of Q1 2018.

Ghost Tree Capital reported no remaining Acceleron Pharma position as of Q1 2018 after selling out during the quarter.
Ghost Tree Capital sold 200,000 Acceleron Pharma shares in Q1 2018, an estimated $8.49M.
Ghost Tree Capital first reported a position in Acceleron Pharma in Q4 2016 and held it in 5 quarters.
Ghost Tree Capital's Acceleron Pharma position peaked at $13.1M in Q3 2017.
150 funds tracked by Wall St. Rank held Acceleron Pharma as of Q1 2018.

Based on Ghost Tree Capital's 13F filing for Q1 2018, filed 15 May 2018.